Written | 2008-05 | Eileen Friedman |
Upstate Medical University, State University of New York, Syracuse, New York 13210, USA |
Identity |
Alias (NCBI) | MIRK |
HGNC (Hugo) | DYRK1B |
HGNC Alias symb | MIRK |
HGNC Alias name | minibrain-related kinase |
HGNC Previous name | dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1B | dual specificity tyrosine-(Y)-phosphorylation regulated kinase 1B |
LocusID (NCBI) | 9149 |
Atlas_Id | 43235 |
Location | 19q13.2 [Link to chromosome band 19q13] |
Location_base_pair | Starts at 39825347 and ends at 39834233 bp from pter ( according to GRCh38/hg38-Dec_2013) [Mapping DYRK1B.png] |
Fusion genes (updated 2017) | Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands) |
DYRK1B (19q13.2) / SENP3 (17p13.1) |
DNA/RNA |
Description | 11 exons and 10 introns encompassing 8.8kb. |
Transcription | Start at exon 1 encodes major active form p69, with alternative splicing in exon 9 giving rise to kinase inactive p62, and with alternative splicing within intron 1-2 giving rise to p75 in skeletal muscle. |
Pseudogene | None reported |
Protein |
Note | Serine/threonine kinase activated by intramolecular phosphorylation on tyrosine. |
Description | 629 amino acids. |
Expression | Widely expressed at low levels, with elevated expression in muscle and testis. |
Function | Mediates myoblast differentiation. |
Mutations |
Note | None in SW480 colon cancer cells, none reported. |
Implicated in |
Note | |
Entity | Ductal adenocarcinoma of the pancreas |
Note | Active kinase in pancreatic cancer cell lines. |
Disease | Present in 89% of cases by immunocytochemistry (25 of 28 cases) |
Cytogenetics | 19q13 amplicon in 10% of cases |
Hybrid/Mutated Gene | None reported |
Abnormal Protein | None reported |
Oncogenesis | Embryonic knockout is viable and has no reported phenotype |
Entity | Rhabdomyosarcoma |
Note | Overexpressed in 12 of 16 cases; active kinase in rhabdomyosarcoma cell lines |
Breakpoints |
Note | None reported |
Bibliography |
The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma. |
Deng X, Ewton DZ, Li S, Naqvi A, Mercer SE, Landas S, Friedman E. |
Cancer Res. 2006 Apr 15;66(8):4149-58. |
PMID 16618736 |
The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer. |
Jin K, Park S, Ewton DZ, Friedman E. |
Cancer Res. 2007 Aug 1;67(15):7247-55. |
PMID 17671193 |
Mirk protein kinase is a mitogen-activated protein kinase substrate that mediates survival of colon cancer cells. |
Lee K, Deng X, Friedman E. |
Cancer Res. 2000 Jul 1;60(13):3631-7. |
PMID 10910078 |
Mirk/Dyrk1b mediates cell survival in rhabdomyosarcomas. |
Mercer SE, Ewton DZ, Shah S, Naqvi A, Friedman E. |
Cancer Res. 2006 May 15;66(10):5143-50. |
PMID 16707437 |
Citation |
This paper should be referenced as such : |
Friedman, E |
DYRK1B (dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1B) |
Atlas Genet Cytogenet Oncol Haematol. 2009;13(4):263-264. |
Free journal version : [ pdf ] [ DOI ] |
External links |
REVIEW articles | automatic search in PubMed |
Last year publications | automatic search in PubMed |
© Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Fri Feb 19 17:49:27 CET 2021 |
For comments and suggestions or contributions, please contact us